Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults
Launched by BLUEPRINT MEDICINES CORPORATION · Feb 26, 2019
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Medically healthy
- • Non-smoker
- • Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2
- • No clinically significant cardiac history
- • No current electrocardiogram (ECG) abnormality
- • Female must not be of childbearing potential
- Exclusion Criteria:
- • History of or current mental or legal incapacitation or major emotional problems
- • History or current clinically significant medical/psychiatric condition/disease
- • History of any illness that, in the opinion of the Investigator, might impact the results of the study or pose an additional risk to the participant
- • History or current alcoholism/drug abuse
- • History or current allergy to the study drug or a similar drug
About Blueprint Medicines Corporation
Blueprint Medicines Corporation is a biopharmaceutical company focused on developing targeted therapies for genomically defined cancers, rare diseases, and cancer immunotherapy. With a commitment to precision medicine, Blueprint Medicines leverages its proprietary drug discovery platform to identify and develop innovative therapeutic candidates that address unmet medical needs. The company is dedicated to transforming patient outcomes through rigorous clinical research, advancing its pipeline of investigational products, and collaborating with healthcare professionals and organizations to ensure broad access to its therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lincoln, Nebraska, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials